Results 241 to 250 of about 88,273 (287)

Modeling and Simulation in Development and Regulatory Approval of Chimeric Antigen Receptor T‐Cell Therapies: An Analysis of European Medicines Agency Centralized Procedures From 2018 to 2024

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 4, April 2026.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapies represent a major advancement in oncology. These therapies have demonstrated therapeutic potential, particularly in hematological malignancies where patients have relapsed or are refractory to prior treatments.
Lisa Hanquet, Jean‐Michel Dogné, Flora T. Musuamba   +2 more
wiley   +1 more source

Use of Modeling and Simulation to Inform the Development of Monoclonal Antibodies to Treat Moderate‐to‐Severe Asthma: A Retrospective Review of EMA Centralized Procedure From 2014 to 2024

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 4, April 2026.
ABSTRACT We present here a repository of key regulatory questions answered in centralized procedures and evaluate the place of modeling and simulation in marketing authorization process for biologics approved for the treatment of moderate‐to‐severe asthma from 2014 to 2024.
Hélène Haguet, Jean‐Michel Dogné, Flora T Musuamba   +2 more
wiley   +1 more source

Synergistic Antitumor Efficacy of Radiofrequency Ablation Combined With TROP2‐CAR‐T Cells in a Xenograft Mouse Model of Lung Adenocarcinoma

Thoracic Cancer, Volume 17, Issue 7, April 2026.
Combining radiofrequency ablation with TROP2‐CAR‐T cells results in synergistic tumor suppression and minimal systemic toxicity in vivo, supporting local ablation as a strategy to enhance CAR‐T therapy for solid tumors. ABSTRACT Background Lung adenocarcinoma (LUAD) is highly relapsed and responds poorly to chimeric antigen receptor (CAR)‐T therapy due
Yanyun Zhao, Peng Jiao, Zhuo Zhang, Yang Sun, Huiyan Sun, Xiaoguang Li, Zhixin Bie, Chenghua Xiao, Yanfei Qu, Wei Wang, Qinqin Xu, Lisheng Wang   +11 more
wiley   +1 more source

Artificial intelligence streamlines scientific discovery of drug–target interactions

British Journal of Pharmacology, Volume 183, Issue 8, Page 1673-1690, April 2026.
Abstract Drug discovery is a complicated process through which new therapeutics are identified to prevent and treat specific diseases. Identification of drug–target interactions (DTIs) stands as a pivotal aspect within the realm of drug discovery and development. The traditional process of drug discovery, especially identification of DTIs, is marked by
Yuxin Yang, Feixiong Cheng
wiley   +1 more source

Mapping Dental Care for Children and Adolescents With Rare Diseases: A Brazilian Multicentre Study

Community Dentistry and Oral Epidemiology, Volume 54, Issue 2, Page 163-173, April 2026.
ABSTRACT Objectives To describe the landscape of dental care provided by specialised centres for children and adolescents with rare diseases (RDs) in the state of Minas Gerais, southeastern Brazil. Methods A retrospective cross‐sectional study was conducted involving individuals aged 0–18 years with a confirmed diagnosis of a RD who received care at ...
Heloisa Vieira Prado, Rayssa Maria Soalheiro de Souza, Gabriella Guerra Freire Gabrich Fonseca, Kamila Rodrigues Junqueira Carvalho, Anna Vitória Mendes Viana Silva, Iasmin Fonseca Tolentino Mascarenhas, Beatriz Rezende Bergo, Hanna Larissa Barbosa Soares, Bárbara Mendes de Jesus, Layanne Ribeiro Ferreira e Sobral, Kélisson Duarte Reis, Késia Lara dos Santos Marques, Fabiana Sodré de Oliveira, Daniella Reis Barbosa Martelli, José Alcides Almeida de Arruda, Benjamin P. J. Fournier, Denise Vieira Travassos, Soraia Macari, Célia Regina Moreira Lanza, Ana Cristina Borges‐Oliveira, Hercílio Martelli‐Júnior, Tarcília Aparecida Silva   +21 more
wiley   +1 more source

Calprotectin and Sarcopenia in COPD: Biomarker, Bystander or Target?

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
Irena Sarc, Ramon Langen, Harry Reinier Gosker, Mitja Lainscak   +3 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Orphan drugs

Abstract Orphan drug designation for the EU, UK, and USA is described, highlighting the requirements and potential incentives on offer for development of medicines for patients with rare diseases.
Phil Ambery, Adrian Kilcoyne, Daniel O’Connor   +2 more
  +4 more sources

[Orphan drugs].

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2001
The paper discusses the problems of orphan drugs from the standpoint of the attitude of state authorities in the USA, Japan, and particularly Europe (the European Union) to their definition and the formation of appropriate legislation--financial provision for the development, production, provision of exclusive sale rights--which warranties the ...
J, Kolár, M, Chalabala, H, Srámková
openaire   +1 more source